A Phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine when administered intramuscularly on a two-dose schedule to subjects who previously received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) studies.
Phase of Trial: Phase III
Latest Information Update: 16 Nov 2017
At a glance
- Drugs GSK 1437173A (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Registrational
- Acronyms Zoster-056
- Sponsors GlaxoSmithKline
- 18 Sep 2017 Planned End Date changed from 2 Jan 2019 to 24 May 2019.
- 18 Sep 2017 Planned primary completion date changed from 2 Jan 2019 to 24 May 2019.
- 06 Jul 2017 Planned primary completion date changed from 1 Nov 2017 to 2 Jan 2019.